Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And those two businesses have brought very good people to the table for us and we rely heavily on those and they've been fantastic for us and they help us obviously along the way to actually embedding those businesses and improving our efficiencies there in reporting |
| And we're so excited about what the future holds for this organization and that we've actually articulated and driven that pathway to profitability |
| So really, really exciting capability upgrade to the team to deliver on the plan that we've got set ahead for ourselves |
| We've got strong momentum in the commercial operations with 29% growth in customer receipts with a global operation now with a comprehensive human and animal health portfolio |
| We've engaged with leading global collaborators, and we've begun our journey with a strong commitment to ESG principles, and we've got a well-defined strategic plan to execute on a multi brand strategy across a number of key jurisdictions |
| As stated before, 29% growth on 2022, an exciting trajectory for the team |
| That's a really great milestone for us to achieve, and that's growing new clinics and new tests every single week |
| Baseline program has been good and it's not without its challenges that we've had |
| This is one of the most amazing pieces of tech are world’s first tech that we are really excited about delivering in the first half of this financial year |
| So we've improved our security posture, particularly with the new businesses as well |
| We've strong momentum in commercial operations with 29% growth in customer receipts to the end of June 30, 2023 |
| It's a really exciting phase for the organization and thanks for the brand and the team are really excited for the year ahead for the EasyDNA brand and the Affinity DNA brands |
| So that's going to be exceptionally exciting |
| So we're very, very excited about what the future holds |
| And it has improved and we've embedded a lot of our processes together in and reporting lines have come together, if you like |
| The vision for this organization to be a world leader in personalized predictive genomics, empowering individuals to truly take control of their health |
| It's off a modest base, but it's showing an incredible trajectory that's over and above the research samples that we do for all of those other institutions |
| So very exciting and part of our team |
| We've engaged leading global collaborators and we've begun the journey on our ESG commitments on ESG principles aligned with World Health Organization, and we've a well-defined strategic plan to execute a multi-brand strategy in key regions |
| We turn cutting-edge science into personalized predictive tests using AI and machine learning techniques to empower physicians and health outcome – better health outcomes for people around the world, enabling a new era of personalized medicine |
| A critical milestone for us over the next 12 months in achieving this pathway to profitability is securing one of those larger payers in the United States to actually help us achieve our goal |
| So that's one that we are really excited about and we are working very hard on and hoping to be able to make an announcement about over the course of the next couple of months |
| So we didn't have the greatest user experience, so we were a little bit delayed there, but the actual launch of that particular website is looking sensational now, and we are really, really happy with it |
| So I'm saying all of this to say, I think we've always had a strong emphasis on that and the processes involved in our business have been there, but we have been improving that of recent time as well |
| An exciting opportunity for us is the launch of the hereditary breast and ovarian cancer test, the 100% comprehensive risk assessment test for hereditary breast and ovarian cancer |
| But it's such an exciting dynamic and fun business to run with the team around the world and we speak with them regularly, our team members there |
| I’m really pleased to have both Simon Morriss, the Chief Executive Officer of Genetic Technologies; and Tony Di Pietro, the CFO of Genetic as well |
| We can increase the number of people we screen, we can increase the number of screening surveillance that we do for those high risk patients and still save the system money by early detection and saving lives |
| GeneType tests grew by 250% in commercial samples |
| 14 test categories, 51 tests and laboratory partners, which help us become successful across the world, there's 12 of those |
| Statement |
|---|
| So obviously bringing into businesses like we have – that have given us that exposure if you like, or an increased exposure to the direct-to-consumer market always presents challenges |
| So it's always a bit of a challenge and it relies on good people in all those regions that we have |
| If they're BRCA negative and they have an elevated risk, they have another pathway |
| So look, again, those challenges too because you've got all these time zones now that it's almost that we have a 24-hour clock on the business now, and we're getting communications over that timeframe in the middle of the night |
| That's why this one is so important because at the moment it's two separate tests and it's quite inconvenient and that we are bringing it into one |
| If they're BRCA negative and their average risk, they'll have another pathway |
| And that can always present challenges |
Please consider a small donation if you think this website provides you with relevant information